Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients

  1. Cécile Alanio
  2. Francesco Nicoli
  3. Philippe Sultanik
  4. Tobias Flecken
  5. Brieuc Perot
  6. Darragh Duffy
  7. Elisabetta Bianchi
  8. Annick Lim
  9. Emmanuel Clave
  10. Marit M van Buuren
  11. Aurélie Schnuriger
  12. Kerstin Johnsson
  13. Jeremy Boussier
  14. Antoine Garbarg-Chenon
  15. Laurence Bousquet
  16. Estelle Mottez
  17. Ton N Schumacher
  18. Antoine Toubert
  19. Victor Appay
  20. Farhad Heshmati
  21. Robert Thimme
  22. Stanislas Pol
  23. Vincent Mallet
  24. Matthew L Albert  Is a corresponding author
  1. Institut Pasteur, France
  2. University Pierre et Marie Curie, France
  3. Albert-Ludwigs-Universität, Germany
  4. Assistance publique - hôpitaux de Paris, France
  5. The Netherlands Cancer Institute, Netherlands
  6. Lunds University, Sweden
  7. Assistance publique - Hôpitaux de Paris, France
  8. Université Paris Descartes, France
  9. Assistance Publique - Hôpitaux de Paris, France
  10. Albert-Ludwigs-Universität Freiburg, Germany

Abstract

Chronic infection perturbs immune homeostasis. While prior studies have reported dysregulation of effector and memory cells, little is known about the effects on naïve T cell populations. We performed a cross-sectional study of chronic hepatitis C (cHCV) patients using tetramer-associated magnetic enrichment to study antigen-specific inexperienced CD8+ T cells (i.e., tumor or unrelated virus-specific populations in tumor-free and sero-negative individuals). cHCV showed normal precursor frequencies, but increased proportions of memory-phenotype inexperienced cells, as compared to healthy donors or cured HCV patients. These observations could be explained by low surface expression of CD5, a negative regulator of TCR signaling. Accordingly, we demonstrated TCR hyperactivation and generation of potent CD8+ T cell responses from the altered T cell repertoire of cHCV patients. In sum, we provide the first evidence that naïve CD8+ T cells are dysregulated during cHCV infection, and establish a new mechanism of immune perturbation secondary to chronic infection.

Article and author information

Author details

  1. Cécile Alanio

    Unités de Recherche Internationales Mixtes Pasteur, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Francesco Nicoli

    Centre d'Immunologie et des Maladies Infectieuses, University Pierre et Marie Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Philippe Sultanik

    Unités de Recherche Internationales Mixtes Pasteur, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Tobias Flecken

    The University Medical Center Freiburg, Department of Internal Medicine II, Albert-Ludwigs-Universität, Freiburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Brieuc Perot

    Unités de Recherche Internationales Mixtes Pasteur, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Darragh Duffy

    Unités de Recherche Internationales Mixtes Pasteur, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Elisabetta Bianchi

    Immunoregulation Unit, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Annick Lim

    Plateforme d'Immunoscope, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Emmanuel Clave

    Hôpital Saint Louis, Assistance publique - hôpitaux de Paris, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Marit M van Buuren

    Department of Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  11. Aurélie Schnuriger

    Laboratoire de virologie, Hôpital Armand-Trousseau, Assistance publique - hôpitaux de Paris, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  12. Kerstin Johnsson

    Mathematics, Faculty of Engineering, Lunds University, Lund, Sweden
    Competing interests
    The authors declare that no competing interests exist.
  13. Jeremy Boussier

    Unités de Recherche Internationales Mixtes Pasteur, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  14. Antoine Garbarg-Chenon

    Laboratoire de virologie, Hôpital Armand-Trousseau, Assistance publique - Hôpitaux de Paris, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  15. Laurence Bousquet

    Institut Cochin, Université Paris Descartes, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  16. Estelle Mottez

    Centre d'Immunologie Humaine, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  17. Ton N Schumacher

    Department of Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  18. Antoine Toubert

    Hôpital Saint-Louis, Assistance publique - hôpitaux de Paris, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  19. Victor Appay

    Centre d'Immunologie et des Maladies Infectieuses, University Pierre et Marie Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  20. Farhad Heshmati

    Etablissement Français du Sang, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  21. Robert Thimme

    The University Medical Center Freiburg, Department of Internal Medicine II, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  22. Stanislas Pol

    Institut Cochin, Université Paris Descartes, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  23. Vincent Mallet

    Institut Cochin, Université Paris Descartes, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  24. Matthew L Albert

    Unités de Recherche Internationales Mixtes Pasteur, Institut Pasteur, Paris, France
    For correspondence
    albertm@pasteur.fr
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Rafi Ahmed, Emory, United States

Ethics

Human subjects: 29 cHCV, 37 SVR, and 18 cHBV patients were included (Table 1). All subjects were followed in the Liver Unit of H�pital Cochin (Paris, France) or the Department of Internal Medicine II (Freiburg, Germany). French samples were obtained as part of study protocol C11-33 approved by the INSERM clinical investigation department with ethical approval from the CPP Ile-de-France II, Paris (ClinicalTrials.gov identifier: n{degree sign}NCT01534728). German samples were obtained in the University Hospital Freiburg according to regulations of local ethic committee. Both study protocols conformed to the ethical guidelines of the Declaration of Helsinki, and patients provided informed consent.

Version history

  1. Received: April 3, 2015
  2. Accepted: November 12, 2015
  3. Accepted Manuscript published: November 14, 2015 (version 1)
  4. Version of Record published: January 19, 2016 (version 2)

Copyright

© 2015, Alanio et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,718
    views
  • 487
    downloads
  • 43
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Cécile Alanio
  2. Francesco Nicoli
  3. Philippe Sultanik
  4. Tobias Flecken
  5. Brieuc Perot
  6. Darragh Duffy
  7. Elisabetta Bianchi
  8. Annick Lim
  9. Emmanuel Clave
  10. Marit M van Buuren
  11. Aurélie Schnuriger
  12. Kerstin Johnsson
  13. Jeremy Boussier
  14. Antoine Garbarg-Chenon
  15. Laurence Bousquet
  16. Estelle Mottez
  17. Ton N Schumacher
  18. Antoine Toubert
  19. Victor Appay
  20. Farhad Heshmati
  21. Robert Thimme
  22. Stanislas Pol
  23. Vincent Mallet
  24. Matthew L Albert
(2015)
Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients
eLife 4:e07916.
https://doi.org/10.7554/eLife.07916

Share this article

https://doi.org/10.7554/eLife.07916

Further reading

    1. Genetics and Genomics
    2. Immunology and Inflammation
    Jean-David Larouche, Céline M Laumont ... Claude Perreault
    Research Article

    Transposable elements (TEs) are repetitive sequences representing ~45% of the human and mouse genomes and are highly expressed by medullary thymic epithelial cells (mTECs). In this study, we investigated the role of TEs on T-cell development in the thymus. We performed multiomic analyses of TEs in human and mouse thymic cells to elucidate their role in T-cell development. We report that TE expression in the human thymus is high and shows extensive age- and cell lineage-related variations. TE expression correlates with multiple transcription factors in all cell types of the human thymus. Two cell types express particularly broad TE repertoires: mTECs and plasmacytoid dendritic cells (pDCs). In mTECs, transcriptomic data suggest that TEs interact with transcription factors essential for mTEC development and function (e.g., PAX1 and REL), and immunopeptidomic data showed that TEs generate MHC-I-associated peptides implicated in thymocyte education. Notably, AIRE, FEZF2, and CHD4 regulate small yet non-redundant sets of TEs in murine mTECs. Human thymic pDCs homogenously express large numbers of TEs that likely form dsRNA, which can activate innate immune receptors, potentially explaining why thymic pDCs constitutively secrete IFN ɑ/β. This study highlights the diversity of interactions between TEs and the adaptive immune system. TEs are genetic parasites, and the two thymic cell types most affected by TEs (mTEcs and pDCs) are essential to establishing central T-cell tolerance. Therefore, we propose that orchestrating TE expression in thymic cells is critical to prevent autoimmunity in vertebrates.

    1. Immunology and Inflammation
    Toyoshi Yanagihara, Kentaro Hata ... Isamu Okamoto
    Research Article

    Anticancer treatments can result in various adverse effects, including infections due to immune suppression/dysregulation and drug-induced toxicity in the lung. One of the major opportunistic infections is Pneumocystis jirovecii pneumonia (PCP), which can cause severe respiratory complications and high mortality rates. Cytotoxic drugs and immune-checkpoint inhibitors (ICIs) can induce interstitial lung diseases (ILDs). Nonetheless, the differentiation of these diseases can be difficult, and the pathogenic mechanisms of such diseases are not yet fully understood. To better comprehend the immunophenotypes, we conducted an exploratory mass cytometry analysis of immune cell subsets in bronchoalveolar lavage fluid from patients with PCP, cytotoxic drug-induced ILD (DI-ILD), and ICI-associated ILD (ICI-ILD) using two panels containing 64 markers. In PCP, we observed an expansion of the CD16+ T cell population, with the highest CD16+ T proportion in a fatal case. In ICI-ILD, we found an increase in CD57+ CD8+ T cells expressing immune checkpoints (TIGIT+ LAG3+ TIM-3+ PD-1+), FCRL5+ B cells, and CCR2+ CCR5+ CD14+ monocytes. These findings uncover the diverse immunophenotypes and possible pathomechanisms of cancer treatment-related pneumonitis.